Novadaq Updates on OPTTX Data Reported at ... ( Visual Acuity Reported to Remain S...)

Novadaq Updates on OPTTX Data Reported at Euroretina

Date:5/29/2008

Visual Acuity Reported to Remain Stable or Improve in 83% of Patients

Studied at 12 Months

TORONTO, May 29 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging and image guidance systems for the operating room, today announced that ophthalmologists from Sacco Hospital in Milan, Italy reported independent 12-month follow-up data on patients treated with the OPTTX(R) System in commercial practice at the recent Euroretina Conference held in Vienna Austria. The 12 month visual acuity (VA) data for those wet-AMD patients followed, some of whom had failed other treatments, continued to support the previously reported six-month data presented at the Association for Research in Vision and Ophthalmology Conference in April 2008 in Fort Lauderdale, FL.

At 12 months, 23 patients were evaluable and the VA for a substantial majority (19, or 83%) of patients studied remained stable or improved. Fourteen of the 23 (61%) had no change or showed a 1-6 line improvement in VA. Five patients lost up to 3 lines and 4 patients lost more than 3 lines in VA. The treating ophthalmologists concluded that the OPTTX technique was safe and reproducible. This study suggests that treatment with OPTTX can be used as an alternative to the anti-VEGF drugs and that it appears that it can be safely applied before, after or in combination with anti-VEGF injections.

"We have been using the OPTTX System in our practice for the past eighteen months. OPTTX has allowed us to stabilize or improve vision in patients, many who had failed previous therapies, and really had no other treatment alternatives," said Giovanni Staurenghi, Professor of Ophthalmology, Chairman Eye Clinic, Director II School of Ophthalmology, Department of Clinical Science Luigi Sacco, Sacco Hospital, University of Milan. "Most importantly, the twelve-month follow-up data demonstrates that the treatment with OPTTX is sustainable
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
2. Novadaq launches PINPOINT: Companys first minimally invasive imaging system
3. Novadaq announces third quarter 2007 conference call and webcast
4. Novadaq to present at Piper Jaffray Healthcare Conference
5. Novadaq to present at BMO Healthcare Conference
6. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
7. Novadaqs SPY System receives clearance for use in organ transplant surgery
8. Novadaq Data Presented at 2008 Society of Thoracic Surgeons Meeting
9. NOVADAQs SPY System to be Featured During Live Broadcast of Robotic Surgery
10. Novadaq to present at Cowen Healthcare Conference
11. Novadaq to hold fiscal 2007 year-end and fourth quarter results conference call and webcast

Post Your Comments:

Novadaq Updates on OPTTX Data Reported at ...( Visual Acuity Reported to Remain S...),Health